Generates revenue primarily from clinical laboratory diagnostic testing services and from pharmaceutical commercialization, including drug sales and licensing/royalty and profit-sharing income from partnered products.
Geographic Exposure
United States76.61%
Chile9.12%
Ireland6.79%
Spain3.45%
Mexico3.35%
Israel0.25%
Revenue Drivers
Clinical laboratory diagnostic services
Specialty and routine lab testing services through BioReference operations.
CORE67.4%
Pharmaceutical sales and licensing
Drug product revenue plus royalties, profit-sharing, and IP-related income.
CORE32.6%
End Markets
Physicians and physician offices
Hospitals and clinics
Oncologists, urologists, OBGYN/MFM providers
Correctional healthcare providers and facilities
Employers and governmental units (testing clients)
Pharmaceutical partners/licensees and distributors
Specializations
Esoteric testing and molecular diagnosticsAnatomic pathology and specialty diagnostics (GenPath)Next-generation sequencing and tumor genomics testingProprietary prostate cancer biomarker testing (4Kscore)Multispecific antibody and vaccine platform (MSTAR)High-potency specialty API manufacturing
Activities
Clinical laboratory testing and pathology services
Pharmaceutical R&D and clinical development
Drug manufacturing and distribution
Sales and marketing to healthcare providers
Out-licensing/collaboration management (milestones and royalties)
